Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy

Mulvihill, David; McMichael, Kevin; Goyal, Sharad; Drachtman, Richard A.; Weiss, Aaron R.; Khan, Atif J.

doi:10.1016/j.radonc.2014.06.018

Cited by 8 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,19,31,[37][38][39][40] This may change in the future following the recent recommendations to treat HL with asymmetric radiation fields. [41][42][43] Secondly, the SBCs of our cohort frequently occurred in the external breast quadrants, as in previous studies among cancer survivors and as in the general population, and were frequently invasive ductal carcinoma. 11,22 Our study inclusion criterion for a minimum dose of 3 Gy evidently makes it impossible to compare the effects of very low dose radiation, or none, with high radiation dose.…”

Section: Discussionsupporting

confidence: 70%

“…Upper outer quadrant disease predominated (36%) and 9.2% were multifocal (Table 2). Of the 141 SBC, 11 (7.8%) were in situ ductal carcinomas with a mean size of 20 mm (range: 2-55 mm), 4 having occurred in contralateral breast disease, (2 synchronous and 2 metachronous), at a mean age of 37 years (range: [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44]. Almost all SBCs (130, 92%) were invasive carcinomas, of which 93% (n = 121) were invasive ductal carcinomas (two with mucinous features), 2.3% (n = 3) invasive lobular carcinomas, 3.1% (n = 4) having both components and 1.5% (n = 2) medullary carcinomas.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy

Supiot

Mahé

Oberlin

et al. 2018

The British Journal of Radiology

View full text Add to dashboard Cite

We found a high proportion of aggressive SBC following thoracic radiotherapy in childhood or early adulthood. Advances in knowledge: SBC screening is recommended by scientific societies for these child/young-adulthood cancer survivors in the same way as the one for high risk women because of constitutional mutations. Our results support these recommendations, not only because of a similar cumulative risk, but also because of the aggressive histological characteristics.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy

Supiot

Mahé

Oberlin

et al. 2018

The British Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…Most commonly reported margins types were GTV-CTV and CTV-PTV margins for thoracic [44, (Fig. 2A), abdominal [15,18,30,41,45,[50][51][52][53][54][55][56]60,[62][63][64]66,70,73,74,[76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94] (Fig. 2B), spinal [43,46,48,63,82, (Fig.…”

Section: Resultsmentioning

confidence: 99%

Pediatric radiotherapy for thoracic and abdominal targets: Organ motion, reported margin sizes, and delineation variations – A systematic review

Meijer¹,

Dijk²,

Huijskens³

et al. 2022

Radiotherapy and Oncology

View full text Add to dashboard Cite

“…Several studies have focused their attention on the reduction of the RT dose to organs at risk and on the other important issue of secondary malignancy, comparing ISRT, INRT or residual volume RT to IFRT in mediastinal lymphomas (28,29). When the residual radiation volume, contoured according to ILROG guidelines, was specifically considered, it should be noted that the mean doses to the right breast, left breast, lung, esophagus and thyroid were lower than those obtained with ISRT and INRT.…”

Section: Discussionmentioning

confidence: 99%

Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study

Sanctis

Rocco

Cox

et al. 2020

In Vivo

View full text Add to dashboard Cite

Aim: To evaluate the efficacy of residual site radiation therapy (RSRT) on local control (LC), progressionfree (PFS) and overall (OS) survival in patients with primary mediastinal lymphoma (PMBCL), following rituximab and chemotherapy treatment (ICHT). Patients and Methods: The study included 34 patients with PMBCL treated between 2006 and 2014 with ICHT with/without autologous stem cell transplantation and RSRT. Between the end of ICHT/stem cell transplantation and RSRT, patients were evaluated with 18 F-fluorodeoxyglucose positron-emission tomography. The gross tumor volume included morphological mediastinal residual disease after ICHT/SCT. The percentage of LC, PFS and OS were assessed. Results: All patients received RSRT with a median dose of 30 Gy. Median follow-up was 82 months. One patient out of 34 (3%) showed progressive disease 9 months from diagnosis. The 10-year PFS and OS were 97% and 97% respectively. Conclusion: RSRT in patients with PMBCL treated with ICHT did not impact unfavorably on LC and patient survival. Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity that accounts for 2-4% of non-Hodgkin's lymphomas. It is characterized by a locally aggressive presentation with a large mediastinal mass, more frequently in young women between the third and the fourth decade (1, 2). The presence of bulky mediastinal disease >10 cm is not uncommon, with extension into the contiguous chest wall, lung and pericardium. A combined approach with doxorubicin-based chemotherapy and adjuvant mediastinal radiotherapy (RT) has been evaluated in retrospective series, most of them performed in the pre-rituximab era, showing a 5-10 years progression-free survival (PFS) of 57-81% (2-5). More recently, the addition of rituximab to the doxorubicinbased chemotherapy schedules (ICHT) and adjuvant RT demonstrated survival improvement, with 3-to 5-year PFS of 80% and overall survival (OS) 83%-88% (1, 2, 6, 7). Although there is a lack of randomized studies, ICHT and adjuvant RT are considered part of the standard of care in the treatment of PMBCL in Italy (2). However, a high cure rate with a 5-year PFS of 93% has been also reported following treatment based on the R-DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab) schedule, without adjuvant RT, but these results, similarly, lack validation by randomized multicentric studies 1407 This article is freely accessible online.

show abstract

Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy

Cited by 8 publications

References 27 publications

Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy

Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy

Pediatric radiotherapy for thoracic and abdominal targets: Organ motion, reported margin sizes, and delineation variations – A systematic review

Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study

Contact Info

Product

Resources

About